Abstract 6058
Background
Cancer-related fatigue (CRF) is one of the most common side effects and leads to a significant impairment of quality of life (QoL). At the same time many cancer patients suffer from malnutrition. Studies show that both physical activity and a good nutritional status reduce CRF. Until now this has only been considered in isolation. This study aims a comprehensive view to evaluate the relation of fatigue with malnutrition and level of activity.
Methods
18 patients of the oncological sports and exercise therapy at the University Hospital Halle (Saale) were examined in a cross-sectional design. Outcome measures were the relevant values of body composition, such as body mass [% of fat-free mass] (BCM [% of FFM]), extracellular mass to body cell mass (ECM / BCM) and phase angle ϕ, which were determined by bioelectrical impedance analysis (BIA). Moreover CRF with EORTC QLQ FA12, Nutritional related QoL with FAACT, History and Current Level of Activity (Questionnaire from Woll) and Malnutrition with Subjective Global Assessment (SGA). The statistical analysis was made with description and Pearson’s correlations. Following, a linear regression analysis was supplemented with an ANOVA.
Results
The correlation between physical fatigue and habitual physical activity had a correlation coefficient of -0.641 (p = 0.004). Between the physical fatigue and FAACT Total Score a negative linear correlation (correlation coefficient = -0.739, p < 0.01) could be found. The correlation of the physical fatigue and the values from the BIA did not show any significant results. The linear regression analysis showed that 47.8 % of the total fatigue could be explained by the Functional Assessment of Anorexia/Cachexia Therapy (corr. R2 = 0.478, p = 0.001) and that ECM/BCM and BCM [% of FFM] do not provide additional explanatory power.
Conclusions
It could be confirmed that the QoL of cancer patients is strongly limited by the CRF. The negative correlation between habitual activity and physical fatigue supports the hypothesis of the so-called "prehabilitation". It has been shown that it is a legitimate strategy to present nutritional status and level of physical activity in cancer patients with CRF at the same time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Jahn: Research grant / Funding (institution): Chugai. C. Leithold: Honoraria (self): Fresenius. All other authors have declared no conflicts of interest.
Resources from the same session
5368 - Durvalumab and Paclitaxel Combination for treatment of metastatic triple negative breast cancer is safe with very promising efficacy
Presenter: Hazem Ghebeh
Session: Poster Display session 3
Resources:
Abstract
1520 - A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Presenter: Daan Hurkmans
Session: Poster Display session 3
Resources:
Abstract
1603 - Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small-cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Presenter: Byoung Cho
Session: Poster Display session 3
Resources:
Abstract
3922 - Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A scale to measure quality of life in cancer patients treated with ICMs
Presenter: Aaron Hansen
Session: Poster Display session 3
Resources:
Abstract
2408 - Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumors
Presenter: Francisco Javier Ros Montana
Session: Poster Display session 3
Resources:
Abstract
3612 - Validation of progression-free survival (PFS) as surrogate endpoint in randomised trials of immune checkpoint inhibitors in advanced solid cancers
Presenter: Peey Sei Kok
Session: Poster Display session 3
Resources:
Abstract
3827 - Pharmacokinetic (PK) analysis of weight-based and fixed dose cemiplimab in patients (pts) with advanced malignancies
Presenter: Michael Migden
Session: Poster Display session 3
Resources:
Abstract
2120 - A burst of highly differentiated CD4 TL identifies a subset of fast progressors, and correlates with hyperprogressive disease in NSCLC patients treated with ICI
Presenter: Hugo Arasanz
Session: Poster Display session 3
Resources:
Abstract
4254 - Nivolumab treatment in advanced non-small cell lung cancer (aNSCLC): a French nationwide retrospective cohort (UNIVOC Study)
Presenter: Christos Chouaid
Session: Poster Display session 3
Resources:
Abstract
1084 - Dissociated responses in patients with metastatic solid tumors treated with immunotherapy
Presenter: Pauline Vaflard
Session: Poster Display session 3
Resources:
Abstract